Simplex Trading’s PharmaCyte Biotech PMCB Stock Holding History

Simplex Trading’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.3K	Sell	19,940 -5,894	-23%	-$4.51K	﹤0.01%	7100
2025 Q4	$18.7K	Buy	25,834 +24,734	+2,249%	+$22.3K	﹤0.01%	6537
2025 Q3	$1K	Buy	+1,100	New	+$1.1K	﹤0.01%	8858
2023 Q4	–	Sell	-199	Closed	–	–	9579
2023 Q3	$0	Sell	199 -46,950	-100%	-$120K	﹤0.01%	9564
2023 Q2	$134K	Sell	47,149 -86,051	-65%	-$258K	﹤0.01%	4743
2023 Q1	$387K	Buy	133,200 +69,592	+109%	+$205K	﹤0.01%	3545
2022 Q4	$186K	Sell	63,608 -1,812	-3%	-$5.19K	﹤0.01%	4313
2022 Q3	$157K	Buy	65,420 +10,493	+19%	+$26.5K	﹤0.01%	4939
2022 Q2	$123K	Buy	+54,927	New	+$120K	﹤0.01%	5279

Other funds holding PMCB

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Simplex Trading's PMCB Position: Q1 2026 in Review

Simplex Trading reduced its PharmaCyte Biotech (PMCB) stake by 23% in Q1 2026, selling an estimated $4.51K and leaving 19,940 shares worth $13.3K. The position accounts for ﹤0.01% of the portfolio, ranked #7100.

Simplex Trading first reported a position in PMCB in Q2 2022 and has held it in 9 quarters since. The position peaked at $387K in Q1 2023. 32 funds tracked by Wall St. Rank hold PMCB as of Q1 2026.

Simplex Trading held 19,940 shares of PharmaCyte Biotech worth $13.3K as of Q1 2026.
Simplex Trading sold 5,894 PharmaCyte Biotech shares in Q1 2026, an estimated $4.51K.
PharmaCyte Biotech made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #7100 holding.
Simplex Trading first reported a position in PharmaCyte Biotech in Q2 2022 and has held it in 9 quarters since.
Simplex Trading's PharmaCyte Biotech position peaked at $387K in Q1 2023.
32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.